Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep203 | Neuroendocrinology | ECE2017

Quality of life in patients with neuroendocrine tumors treated with 177Lu-[DOTA0,Tyr3]-octreotate: a Single Tertiary Care Portuguese Center Experience

Lages Adriana , Moreira Helder , Costa Gracinda , Oliveira Patricia , Oliveira Diana , Martins Diana , Ventura Mara , Cunha Nelson , Carrilho Francisco

Introduction and purpose: 177Lu-[DOTA0,Tyr3]octreotate (177Lu-DOTA-TATE) is a radiopharmaceutical frequently used in peptide receptor radionuclide therapy (PRRT), which is a promising treatment modality in patients with metastasized neuroendocrine tumors (NETs). We purpose to evaluate the quality of life (QoL) in patients with somatostatin receptor positive inoperable or metastatic NETs throughout the three cycle’s (with three months intervals) proto...